Desirudin: A Summary of Recent Data in Patients With or at Risk for Heparin-Induced Thrombocytopenia
A supplement to CHEST Physician and this supplement was sponsored by Canyon Pharmaceuticals.
To view the supplement, click the image above. To take the CME test, follow the test instructions on the last page. Requires Adobe Acrobat Reader.
Topics
- Incidence of HIT
- Costs of Treatment
- Diagnosis of HIT
- Overview of the PREVENT-HIT Study
- PREVENT-HIT Renal Impairment Subanalysis
- PREVENT-HIT Health Economics Subanalysis
- Perioperative Use of Desirudin in Patients With and Without HIT Undergoing Orthopedic Surgery: The DESIRE Registry
- Perioperative Use of Desirudin in Patients With Heparin Antibodies Undergoing CABG
- Summary and Conclusions
Faculty/Faculty Disclosure
Jerrold H. Levy, MD, FAHA
Department of Anesthesiology and Critical Care
Emory University School of Medicine and Emory Healthcare
Atlanta, Georgia
Dr Levy reports that he served as a member of the steering committee for Canyon Pharmaceuticals.
Jeanine M. Walenga, PhD
Cardiovascular Institute
Loyola University Medical Center
Maywood, Illinois
Dr Walenga reports that she has no relevant conflicts to disclose.
Copyright © 2011 Elsevier Inc.
